Plethico Pharmaceuticals Peer Comparison

NSE: PLETHICO | BSE: 532739

₹7.94

₹-0.41 (-4.91%)

As on 13-Jun-2016IST

Market cap

₹27 Cr

Revenue (TTM)

₹765 Cr

P/E Ratio

P/B Ratio

Div. Yield

0 %

Edit

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Market cap (₹ Cr)	27	32,770	31,826	30,814	26,650
Revenue (₹ Cr)	765	1,593	9,779	3,564	1,936
Net Profit (₹ Cr)	-277.72	438.64	-270.51	414.00	288.22
Net Margin (%)	-36.30	27.16	-2.71	11.23	14.79
RoE (%)	-3.05	25.02	-2.55	8.38	29.77
Price to Earnings	--	74.62	--	75.34	92.47
Price-To-Book	0.02	17.64	3.91	6.12	19.85

Income Statement (₹ Cr)

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Operating Revenue	1,631.54	33.90	--	4,350.50	34.80
Total Income	1,664.40	34.61	--	4,375.84	34.80
Total Expenditure	1,470.36	30.42	--	2,996.79	25.65
EBITDA	161.19	3.48	--	1,353.71	9.15
Depreciation	17.73	1.05	--	115.07	2.71
EBIT	143.46	2.42	--	1,238.64	6.44
Interest	67.04	1.10	--	269.02	2.51
Other Income	32.86	0.71	--	25.34	0.42
Exceptional Items	-63.00	--	--	-473.77	--
Profit before Tax	109.28	2.03	--	521.19	3.93
Provision for Tax	7.79	0.68	--	221.74	1.40
Profit after Tax	101.49	1.35	--	299.45	2.52

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Shareholder's Funds	1,366.97	6.11	--	1,471.02	37.49
Minority Interest	--	--	--	--	--
Non-Current Liabilities	259.47	0.04	--	2,891.88	5.39
Current Liabilities	1,096.26	15.82	--	1,890.94	24.92
Total Liabilities	2,731.65	22.09	--	6,253.84	67.79

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Non-Current Assets	1,021.84	5.51	--	3,772.33	47.64
Current Assets	1,700.86	16.45	--	2,481.51	20.15
Total Assets	2,731.65	22.09	--	6,253.84	67.79
Total Debt*	1,187.23	6.41	--	3,492.50	19.14
Net Current Assets	604.59	0.63	--	590.57	-4.76
Contingent Liabilities	234.37	--	--	46.91	0.71

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Cash From Operating Activities	-61.01	--	--	1,343.83	5.07
Cash Flow from Investing Activities	7.52	--	--	-305.45	-4.60
Cash from Financing Activities	-40.51	--	--	-826.56	-0.83
Net Cash Inflow / Outflow	-94.00	0.00	--	211.82	-0.36

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
ROCE (%)	7.07	25.61	--	16.20	12.09
ROE (%)	7.48	24.87	--	66.74	14.65
ROA (%)	3.85	6.42	--	4.97	4.06
EBIT Margin (%)	11.89	12.34	--	31.70	26.29
Net Margin (%)	6.10	3.90	--	6.84	7.25
Cash Profit Margin (%)	7.31	6.56	--	9.52	15.04

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Revenue Growth (%)	5.17	21.86	--	15.97	65.29
EBIT Growth (%)	-35.45	27.63	--	29.05	42.04
Net Profit Growth (%)	-1.38	7.55	--	212.90	6.25
EPS Growth (%)	-1.38	7.55	--	278.36	6.25
Book Value Growth (%)	1.64	28.51	--	253.45	15.81

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Price / Earnings	10.26	0.00	--	17.64	0.00
Price / Book Value	0.76	0.00	--	9.37	0.00
Dividend Yield (%)	0.00	--	--	0.00	--
EV/EBITDA	11.32	1.71	--	7.33	4.36
Market Cap (₹ Cr)	1,041.09	0.00	--	6,555.46	0.00

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Debt to Equity	0.87	1.05	--	2.39	0.51
Short term debt to equity ratio	0.16	0.88	--	0.18	0.21
Current Ratio	1.55	1.04	--	1.31	0.81
Quick Ratio	1.38	0.66	--	0.84	0.77
Interest Coverage	2.63	2.86	--	2.94	2.57

	Plethico Pharmaceuticals	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Debtors to sales (%)	75.01	24.27	--	17.44	42.51
Asset Turnover	0.62	1.74	--	0.72	0.56
Receivable days	245.46	81.45	--	57.17	120.33
Inventory Days	41.56	45.36	--	67.16	9.04
Payable days	23.59	134.63	--	116.25	535.25
Cash Conversion Cycle	263.43	-7.82	--	8.07	-393.94

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.